Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 999,039
  • Shares Outstanding, K 39,178
  • Annual Sales, $ 53,020 K
  • Annual Income, $ -36,560 K
  • 60-Month Beta 1.47
  • Price/Sales 19.32
  • Price/Cash Flow N/A
  • Price/Book 3.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.60
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.69
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -1.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.52 +14.78%
on 08/05/19
27.19 -9.16%
on 08/19/19
+0.39 (+1.60%)
since 07/22/19
3-Month
16.80 +47.02%
on 05/23/19
27.19 -9.16%
on 08/19/19
+7.04 (+39.86%)
since 05/22/19
52-Week
10.72 +130.41%
on 12/24/18
27.19 -9.16%
on 08/19/19
+10.81 (+77.83%)
since 08/22/18

Most Recent Stories

More News
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -10.91% and 8.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 24.70 (-3.14%)
Zymeworks Reports 2019 Second Quarter Financial Results

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019.

ZYME : 24.70 (-3.14%)
Zymeworks' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Zymeworks.

ZYME : 24.70 (-3.14%)
Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has selected a...

CELGZ : 0.54 (unch)
ZYME : 24.70 (-3.14%)
Red Hot Stocks Ahead of G20 Summit

Red Hot Stocks Ahead of G20 Summit

MU : 44.78 (+1.38%)
ARNC : 25.10 (-0.40%)
NKE : 83.31 (+0.69%)
ZYME : 24.70 (-3.14%)
BA : 354.41 (+4.24%)
Will Zymeworks Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Zymeworks.

ZYME : 24.70 (-3.14%)
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option to Purchase Additional Shares

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical stage biopharmaceutical company developing multifunctional biotherapeutics (the "Company"), announced today the closing of its previously announced underwritten...

ZYME : 24.70 (-3.14%)
Zymeworks Announces Pricing of $175.0 Million Public Offering

SOURCE: Zymeworks Inc.

ZYME : 24.70 (-3.14%)
Zymeworks Adds Accomplished Biopharmaceutical Executives to its Board of Directors

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of two new independent members to its...

AMGN : 203.42 (-0.25%)
ZYME : 24.70 (-3.14%)
Zymeworks and GSK Expand 2016 Azymetric(TM) Bispecific Agreement

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration...

ZYME : 24.70 (-3.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ZYME with:

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 25.95
1st Resistance Point 25.32
Last Price 24.70
1st Support Level 24.07
2nd Support Level 23.44

See More

52-Week High 27.19
Last Price 24.70
Fibonacci 61.8% 20.90
Fibonacci 50% 18.95
Fibonacci 38.2% 17.01
52-Week Low 10.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar